Sobanska A, Sobanski A, Wanat K
Pharmaceutics. 2025; 17(2).
PMID: 40006523
PMC: 11859714.
DOI: 10.3390/pharmaceutics17020156.
Giri B, Jakka D, Sandoval M, Kulkarni V, Bao Q
Pharmaceutics. 2024; 16(10).
PMID: 39458654
PMC: 11511072.
DOI: 10.3390/pharmaceutics16101325.
Rupenthal I, Agarwal P
Handb Exp Pharmacol. 2023; 284:267-288.
PMID: 37620616
DOI: 10.1007/164_2023_693.
Zhang R, Yang J, Luo Q, Shi J, Xu H, Zhang J
Drug Deliv. 2022; 29(1):2217-2233.
PMID: 35815765
PMC: 9275503.
DOI: 10.1080/10717544.2022.2096714.
Balla A, Auriola S, Grey A, Demarais N, Valtari A, Heikkinen E
Pharmaceutics. 2021; 13(5).
PMID: 34064499
PMC: 8147976.
DOI: 10.3390/pharmaceutics13050658.
Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures.
Afify E, Elsayed I, Gad M, Mohamed M, Afify A
PLoS One. 2018; 13(2):e0191415.
PMID: 29401498
PMC: 5798776.
DOI: 10.1371/journal.pone.0191415.
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.
Mandal A, Pal D, Agrahari V, Trinh H, Joseph M, Mitra A
Adv Drug Deliv Rev. 2018; 126:67-95.
PMID: 29339145
PMC: 5995646.
DOI: 10.1016/j.addr.2018.01.008.
Tailored nanostructured platforms for boosting transcorneal permeation: Box-Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization.
Elsayed I, Sayed S
Int J Nanomedicine. 2017; 12:7947-7962.
PMID: 29133980
PMC: 5669792.
DOI: 10.2147/IJN.S150366.
Oxidative Stress Levels in Aqueous Humor from High Myopic Patients.
Kim E, Kim H, Hyon J, Wee W, Shin Y
Korean J Ophthalmol. 2016; 30(3):172-9.
PMID: 27247516
PMC: 4878977.
DOI: 10.3341/kjo.2016.30.3.172.
Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits.
Kida T, Kozai S, Takahashi H, Isaka M, Tokushige H, Sakamoto T
PLoS One. 2014; 9(5):e96481.
PMID: 24796327
PMC: 4010472.
DOI: 10.1371/journal.pone.0096481.
Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations.
Wen Q, Trokel S, Kim M, Paik D
Cornea. 2012; 32(2):179-84.
PMID: 22868628
PMC: 3493702.
DOI: 10.1097/ICO.0b013e31825646de.
Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
Kadam R, Jadhav G, Ogidigben M, Kompella U
Drug Metab Dispos. 2011; 39(9):1529-37.
PMID: 21673129
PMC: 3164276.
DOI: 10.1124/dmd.111.040055.
Potential of the bioflavonoids in the prevention/treatment of ocular disorders.
Majumdar S, Srirangam R
J Pharm Pharmacol. 2010; 62(8):951-65.
PMID: 20663029
PMC: 4372466.
DOI: 10.1211/jpp.62.08.0001.
Prediction of the corneal permeability of drug-like compounds.
Kidron H, Vellonen K, Del Amo E, Tissari A, Urtti A
Pharm Res. 2010; 27(7):1398-407.
PMID: 20387098
DOI: 10.1007/s11095-010-0132-8.
Spinal disposition and meningeal permeability of local anesthetics.
Clement R, Malinovsky J, Hildgen P, Dollo G, Estebe J, Chevanne F
Pharm Res. 2004; 21(4):706-16.
PMID: 15139529
DOI: 10.1023/b:pham.0000022419.18144.9e.
[Transcorneal-paracorneal penetration route for topical application of drugs to the eyt. Mycophenolate mofetil as a model substance].
Bertelmann E, Knapp S, Rieck P, Keipert S, Hartmann C, Pleyer U
Ophthalmologe. 2003; 100(9):696-701.
PMID: 14504893
DOI: 10.1007/s00347-003-0898-8.
Pharmacokinetic transfer functions and generalized clearances.
Siegel R
J Pharmacokinet Biopharm. 1986; 14(5):511-21.
PMID: 3806373
DOI: 10.1007/BF01059658.
Ocular pharmacokinetic models of clonidine-3H hydrochloride.
Chiang C, Schoenwald R
J Pharmacokinet Biopharm. 1986; 14(2):175-211.
PMID: 3746638
DOI: 10.1007/BF01065260.
Morphology of the pig cornea in normal conditions and after incubation in a perfusion apparatus.
Camber O, Rehbinder C, Nikkila T, EDMAN P
Acta Vet Scand. 1987; 28(2):127-34.
PMID: 3447467
PMC: 8185779.
Ocular drug delivery. Pharmacokinetic considerations.
Schoenwald R
Clin Pharmacokinet. 1990; 18(4):255-69.
PMID: 2182264
DOI: 10.2165/00003088-199018040-00001.
